Your browser is no longer supported. Please, upgrade your browser.
PIRS Pieris Pharmaceuticals, Inc. monthly Stock Chart
PIRS [NASD]
Pieris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own0.23% Shs Outstand45.28M Perf Week6.27%
Market Cap260.81M Forward P/E- EPS next Y-1.02 Insider Trans-32.82% Shs Float45.28M Perf Month19.75%
Income-39.90M PEG- EPS next Q-0.23 Inst Own57.20% Short Float4.58% Perf Quarter26.32%
Sales27.10M P/S9.62 EPS this Y-25.50% Inst Trans-7.56% Short Ratio3.48 Perf Half Y84.62%
Book/sh0.40 P/B14.40 EPS next Y-13.30% ROA-28.80% Target Price7.33 Perf Year6.47%
Cash/sh2.20 P/C2.62 EPS next 5Y- ROE-114.20% 52W Range2.39 - 6.04 Perf YTD116.54%
Dividend- P/FCF- EPS past 5Y- ROI-76.50% 52W High-4.64% Beta1.32
Dividend %- Quick Ratio2.70 Sales past 5Y18.60% Gross Margin- 52W Low141.00% ATR0.38
Employees107 Current Ratio2.70 Sales Q/Q-54.70% Oper. Margin- RSI (14)63.09 Volatility7.72% 7.76%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume6.27 Prev Close5.28
ShortableYes LT Debt/Eq0.00 EarningsAug 15 Payout- Avg Volume596.58K Price5.76
Recom1.80 SMA2016.98% SMA5017.47% SMA20053.60% Volume3,477,587 Change9.09%
Jul-30-19Downgrade Robert W. Baird Outperform → Neutral
May-14-19Initiated Robert W. Baird Outperform $5
Mar-19-18Initiated Jefferies Buy $12
Mar-19-18Initiated Evercore ISI Outperform $13
Jan-16-18Reiterated H.C. Wainwright Buy $9 → $12
May-30-17Initiated Rodman & Renshaw Buy $9
Aug-05-16Resumed ROTH Capital Buy
Aug-12-15Initiated JMP Securities Mkt Outperform
Jul-27-15Initiated Oppenheimer Outperform $8
Jul-22-15Initiated ROTH Capital Buy $7
Sep-03-19 07:30AM  Pieris Pharmaceuticals Announces Changes to Senior Management Team ACCESSWIRE
Aug-29-19 08:00AM  Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences ACCESSWIRE +5.10%
Aug-27-19 07:28PM  Edited Transcript of PIRS earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
11:26AM  Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Aug-01-19 07:00AM  Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update ACCESSWIRE
06:55AM  Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors ACCESSWIRE
Jul-29-19 02:23PM  PIRS Stock Surges on Promising Drug Data Ahead of Earnings Schaeffer's Investment Research +12.21%
Jul-25-19 08:00AM  Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019 ACCESSWIRE
Jul-11-19 01:58PM  Do Institutions Own Shares In Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)? Simply Wall St.
Jun-23-19 04:32PM  Did Hedge Funds Drop The Ball On Pieris Pharmaceuticals, Inc. (PIRS)? Insider Monkey
Jun-12-19 12:16PM  These 4 Charts Are Looking Better And Better Benzinga
May-31-19 08:40AM  Implied Volatility Surging for Pieris Pharmaceuticals (PIRS) Stock Options Zacks -6.12%
May-30-19 08:00AM  Pieris Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference ACCESSWIRE
May-22-19 02:30PM  Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4R Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference ACCESSWIRE
11:25AM  Edited Transcript of PIRS earnings conference call or presentation 10-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-14-19 08:00AM  Pieris Pharmaceuticals to Present at the 2019 RBC Capital Markets Global Healthcare Conference ACCESSWIRE +9.86%
May-10-19 07:00AM  Pieris Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update ACCESSWIRE
May-03-19 08:00AM  Pieris Pharmaceuticals to Host First Quarter 2019 Investor Call and Corporate Update on May 10, 2019 ACCESSWIRE +5.98%
May-02-19 10:33AM  Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-28-19 09:20AM  Did You Miss Pieris Pharmaceuticals's (NASDAQ:PIRS) 56% Share Price Gain? Simply Wall St.
Apr-03-19 08:50AM  Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference ACCESSWIRE +5.99%
Apr-02-19 08:00AM  Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting ACCESSWIRE
Apr-01-19 06:25PM  Edited Transcript of PIRS earnings conference call or presentation 12-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-12-19 07:00AM  Pieris Pharmaceuticals Reports 2018 Year-End Cash Position and Provides Corporate Update ACCESSWIRE
06:00AM  Pieris Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-19 08:00AM  Pieris Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference ACCESSWIRE
Mar-05-19 08:00AM  Pieris Pharmaceuticals to Host Full-Year 2018 Investor Call and Corporate Update on March 12, 2019 ACCESSWIRE
Feb-26-19 07:45AM  Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A New Research Emphasizes Economic Growth GlobeNewswire
Feb-21-19 01:22PM  Does Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Have A Particularly Volatile Share Price? Simply Wall St.
Jan-09-19 02:40PM  What Kind Of Shareholder Appears On The Pieris Pharmaceuticals, Inc.s (NASDAQ:PIRS) Shareholder Register? Simply Wall St.
Dec-21-18 10:45AM  These 4 Pharma Stocks Could Test December Highs ACCESSWIRE
Dec-17-18 10:44PM  Should You Buy Pieris Pharmaceuticals, Inc. (PIRS)? Insider Monkey
Dec-04-18 02:24PM  How Much Did Pieris Pharmaceuticals Incs (NASDAQ:PIRS) CEO Pocket Last Year? Simply Wall St.
Nov-27-18 08:15AM  New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-14-18 09:46PM  Edited Transcript of PIRS earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 04:22PM  P.A.W. Capital Partners Returns, AUM, and Holdings Insider Monkey -7.77%
Nov-08-18 08:00AM  Pieris Pharmaceuticals to Present at Investor Conferences in November GlobeNewswire
Nov-07-18 09:00AM  Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates Zacks -13.47%
07:56AM  Pieris Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM  Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-18 08:00AM  Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018 GlobeNewswire
Oct-25-18 08:16AM  Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors GlobeNewswire
Oct-16-18 12:09PM  Are Pieris Pharmaceuticals Incs (NASDAQ:PIRS) Interest Costs Too High? Simply Wall St.
08:15AM  New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-02-18 08:00AM  Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-25-18 08:00AM  Pieris Pharmaceuticals to Present at Investor Conferences in October GlobeNewswire +6.75%
Sep-14-18 08:00AM  Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4R Antagonist AZD1402/PRS-060 at the ERS International Congress 2018 GlobeNewswire
Sep-10-18 08:00AM  Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors GlobeNewswire
Sep-04-18 08:00AM  Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy GlobeNewswire
Aug-30-18 08:00AM  Pieris Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-27-18 01:54AM  Edited Transcript of PIRS earnings conference call or presentation 9-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-15-18 08:00AM  New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -6.83%
Aug-09-18 08:30AM  Pieris Pharmaceuticals (PIRS) Reports Break-Even Earnings for Q2 Zacks
07:28AM  Pieris Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
06:00AM  Pieris Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-18 08:00AM  Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018 GlobeNewswire
Jul-18-18 07:45AM  Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities ACCESSWIRE
May-31-18 08:00AM  Pieris Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-20-18 09:07PM  Should You Be Content With Pieris Pharmaceuticals Incs (NASDAQ:PIRS) Earnings Growth? Simply Wall St.
May-15-18 07:25PM  Edited Transcript of PIRS earnings conference call or presentation 10-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-10-18 07:50AM  Pieris Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-03-18 08:00AM  Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference GlobeNewswire
May-01-18 08:00AM  Pieris Pharmaceuticals to Host First Quarter 2018 Investor Call and Corporate Update on May 10, 2018 Marketwired
Apr-27-18 07:35AM  Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem Discovering Underlying Factors of Influence GlobeNewswire
Apr-25-18 08:00AM  Pieris Pharmaceuticals Appoints Ann Barbier, M.D., Ph.D., to its Board of Directors Marketwired
Mar-10-18 08:11PM  Edited Transcript of PIRS earnings conference call or presentation 9-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
Mar-09-18 06:00AM  Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results and Corporate Update Marketwired
Mar-06-18 08:30AM  Pieris Pharmaceuticals to Present at Investor Conferences in March Marketwired
Feb-28-18 09:00AM  Pieris Pharmaceuticals to Host Full-Year 2017 Investor Call and Corporate Update on March 9, 2018 Marketwired
08:25AM  Consolidated Research: 2018 Summary Expectations for Electronics for Imaging, First Hawaiian, Magellan Midstream Partners, Visteon, Pieris Pharmaceuticals, and Cincinnati Bell Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-19-18 08:30AM  Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference Marketwired
Feb-16-18 05:36PM  Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares Marketwired
Feb-14-18 12:27AM  Pieris Pharmaceuticals Announces Pricing of its Public Offering Marketwired -7.94%
Feb-13-18 04:01PM  Pieris Pharmaceuticals Announces Public Offering of Common Stock Marketwired +6.42%
Feb-12-18 10:32AM  Heres Whats Moving Pieris Pharmaceuticals And Valeant Pharmaceuticals Market Exclusive
07:20AM  Wired News Pieris Pharma Collaborated with Seattle Genetics to Develop Immuno-Oncology Treatments ACCESSWIRE
Feb-09-18 06:45AM  Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration Business Wire +20.14%
06:45AM  Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Marketwired
Feb-02-18 02:29PM  Is Pieris Pharmaceuticals Inc (NASDAQ:PIRS) As Financially Strong As Its Balance Sheet Indicates? Simply Wall St. +5.22%
Jan-29-18 08:30AM  Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th Marketwired
Jan-08-18 06:03AM  The 10 Best Stocks of 2017 Motley Fool
Jan-02-18 07:30AM  Consolidated Research: 2018 Summary Expectations for Pieris Pharmaceuticals, Cincinnati Bell, FormFactor, Belden, Watts Water Technologies, and Anixter International Fundamental Analysis, Key Performance Indications GlobeNewswire
Dec-27-17 11:40AM  ETFs with exposure to Pieris Pharmaceuticals, Inc. : December 27, 2017 Capital Cube
08:51AM  Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session Zacks
Dec-14-17 09:43AM  4 Top-Ranked Biotech Stocks Under $20 With Room for Growth Zacks
Dec-07-17 08:30AM  Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402 Marketwired
Nov-30-17 02:14PM  ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 30, 2017 Capital Cube
Nov-29-17 07:57AM  Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-21-17 08:30AM  Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors Marketwired
Nov-14-17 07:14AM  Edited Transcript of PIRS earnings conference call or presentation 9-Nov-17 3:00pm GMT Thomson Reuters StreetEvents
Nov-09-17 01:03PM  ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 9, 2017 Capital Cube +9.83%
09:05AM  Pieris Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-08-17 07:57PM  Pieris Pharmaceuticals reports 3Q loss Associated Press
04:30PM  Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update Marketwired
Nov-02-17 08:00AM  Pieris Pharmaceuticals to Host Third Quarter 2017 Investor Call and Corporate Update on November 9, 2017 Marketwired
Nov-01-17 08:00AM  Pieris Pharmaceuticals to Present at Investor Conferences in November Marketwired
Oct-27-17 11:11AM  ETFs with exposure to Pieris Pharmaceuticals, Inc. : October 27, 2017 Capital Cube
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerSep 06Sale4.5050,000224,970314,139Sep 10 06:00 PM